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Objectives: The objectives of the presented study were to estimate societal costs of COPD in
Sweden, the relationship between costs and disease severity, and possible changes in the costs
during the last decade.
Methods: Subjects with COPD derived from the general population in Northern Sweden were
interviewed by telephone regarding their resource utilisation and productivity losses four
times quarterly during 2009e10. Mean annual costs were estimated for each severity stage
of COPD.
Results: A strong relationship was found between disease severity and costs. Estimated mean
annual costs per subject of mild, moderate, severe and very severe COPD amounted to 596
(SEK 5686), 3245 (SEK 30,957), 5686 (SEK 54,242), and 17,355 euros (SEK 165,569), respectively.
The main cost drivers for direct costs were hospitalisations (for very severe COPD) and drugs
(all other severity stages). The main cost driver for indirect costs was productivity loss due
to sick-leave (for mild COPD) and early retirement (all other severity stages). Costs appeared
to be lower in 2010 than in 1999 for subjects with severe and very severe COPD, but higher fornterval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; GOLD,
ve Lung Disease; OLIN, Obstructive Lung Disease in Northern Sweden; SEK, Swedish Krona.
dies, Norrbotten County Council, Robertsviksgatan 9, SE-971 89 Lulea˚, Sweden. Tel.: þ46 76 1041336;
@ki.se (S.-A. Jansson).
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1932 S.-A. Jansson et al.those with mild and moderate COPD.
Conclusion: Our results show that costs of COPD are strongly related to disease severity, and
scaling the data to the whole Swedish population indicates that the total costs in Sweden
amounted to 1.5 billion euros (SEK 13.9 bn) in 2010. In addition, costs have decreased since
1999 for subjects with severe and very severe COPD, but increased for those with mild and
moderate COPD.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
most common chronic and disabling diseases worldwide
with substantial morbidity and mortality [1]. The main risk
factors are smoking and increasing age and the prevalence
is high [2e6]. COPD places a major burden on healthcare
systems, and has substantial economic effects [7e12].
However, although it is important to acquire knowledge of
the societal burden of highly prevalent, chronic diseases,
most analyses of its economic effects to date have been
“top-down” studies, based on administrative data.
Furthermore, very few studies (if any) have examined re-
lationships between the costs and severity of the disease in
recent years. We have previously shown that results of
“bottom-up” studies of the general population yield higher
estimates of costs than top-down studies, due to under-
diagnosis of COPD [7]. Thus, there is a need for further
knowledge of the societal costs of COPD for the general
population, based on recently compiled health economic
data from bottom-up studies.
Cost-of-illness studies examine the societal costs of
diseases and usually include both direct (associated with
prevention, diagnostics, treatment, rehabilitation and all
other elements of medical care) and indirect (associated
with mortality, productivity losses due to absenteeism and
presenteeism, and informal care) costs [13]. The Obstruc-
tive Lung Disease in Northern Sweden (OLIN) studies have
collected epidemiological data on obstructive lung diseases
and allergies for 27 years [2]. In a previous cost-of-illness
study of COPD, we found a highly significant relationship
between disease severity and costs [7]. Estimated societal
costs of COPD for Sweden amounted to ca. 1.0 billion euros
(SEK 9.1 bn) in 1999, corresponding to 1.1 bn euros (SEK
10.7 bn) in 2010 with Consumer Price Index adjustment
[14].
The objectives of the presented study were to estimate
current societal costs of COPD in Sweden, the relationship
between costs and disease severity, the main cost drivers,
and possible changes in costs from 1999 to 2009e10 (esti-
mated using the same methods) [7].Material and methods
Data were collected prospectively by telephone interviews
over one year from a well-defined, representative cohort of
subjects with COPD aged 39e84 years living in northern
Sweden. The Ethics Committee at the University Hospital of
northern Sweden in Umea˚ approved the study.Study population
In 2002e2004, samples of the general population of north-
ern Sweden were clinically examined as part of the
Obstructive Lung Disease in Northern Sweden (OLIN)
Studies. Based on these examinations, which included lung
function tests, a cohort of 993 subjects was identified as
having COPD [15], as defined by the Global initiative for
chronic Obstructive Lung Disease (GOLD) [16,17] spiro-
metric criteria. The 993 subjects with COPD have been
invited to yearly examinations since 2005. The current
study population was identified in 2008e2009 from these
993 subjects, and the COPD severity grading was based on
spirometry tests in 2008e2009.
Due to low numbers of subjects with severe and very
severe COPD, all subjects with FEV1 <50% of predicted
values were invited to participate in the study, and two
random samples were drawn from subjects with mild and
moderate COPD, respectively. In total, 275 subjects (47.3%
women) with COPD were invited to take part in the study,
and 244 (89%) participated. The demographic characteris-
tics by disease severity are shown in Table 1.
Reasons for non-participation were as follows: four
subjects were not able to participate in the interviews due
to various diseases, four did not speak Swedish, one had
died, nine could not be reached and 13 declined to
participate. No significant differences were found in de-
mographic characteristics between participants and non-
participants.
Methods
The same questionnaire as in the study performed in 1999
[7] was used and is presented in an Online Appendix. An
invitation letter including information about the study was
mailed to the invited subjects before study start. As in the
1999 study, the participants were interviewed four times
quarterly by telephone in 2009e2010, regarding their
resource utilisation and productivity losses. Quarterly in-
tervals were chosen because three months is reportedly a
suitable time for minimising recall bias [18]. In addition, a
diary was maintained after the first, second and third in-
terviews in order to further reduce any recall bias. All in-
terviews were carried out by the same person (S-A J), as in
the 1999 study.
A total of 235 subjects participated in all four planned
interviews. Six died during the study and no costs were
assigned to them after their death. The remaining three did
not participate in all planned quarterly interviews, and
their costs were imputed equal to the average annual costs
Table 1 Participants in 2009e2010 by age, gender, severity of disease, and smoking habits.
COPD severity stage (GOLD) Total
Very severe Severe Moderate Mild
<30% 30e49% 50e79% 80%
n Z 14 n Z 29 n Z 85 n Z 116 n Z 244
Mean age, years (range) 67 (44e81) 70 (56e84) 67 (39e84) 68 (52e79) 68 (39e84)
Male, n (%) 7 (50) 17 (59) 47 (55) 57 (49) 128 (52)
Smoking habits, n (%)
Non-smokers 0 (0) 2 (7) 19 (22) 34 (29) 55 (23)
Ex-smokers 10 (71) 17 (59) 37 (44) 53 (46) 117 (48)
Current smokers 4 (29) 10 (34) 29 (34) 29 (25) 72 (30)
Costs of COPD 1933in the available interviews, according to the “patient-year
approach” method [19].
Costs
Mean annual direct and indirect costs per subject were
estimated for each severity stage of COPD by multiplying
the resource use and productivity losses associated with
respiratory diseases with the unit costs, based on average
annual exchange rates for 2010 (1 euro Z SEK 9.54) [20].
The results from 1999 [7] were adjusted to 2010 values
using the overall Consumer Price Index [14] to enable
comparison with those obtained in the present study.
Unit costs
Unit costs for health-care resources were obtained from the
Northern healthcare region’s price list of 2010 [21], which
includes all costs for the health-care sector per visit to
outpatient care or per day in hospital (Table 2). Costs of
drugs were based on prices listed by the Dental andTable 2 Unit costs in 2010, euros.
Type of cost Unit Unit costa
Primary care physician Visit 177




Physician, dept. of medicine Visit 301
Physician, emergency room Visit 312
Other hospital-based personnel Visit 166




Hospitalisation, dept. of medicine Day 643
Hospitalisation, dept. of infection Day 606
Hospitalisation, intensive care Day 3249
Oxygen therapy Month 137
Labour cost Day 191
a Unit costs for health-care resources are obtained from the
Northern healthcare region’s price list. The labour cost is the
average salary per day in Sweden including payroll tax and se-
curity contributions.Pharmaceutical Benefits Agency, which reflect retail phar-
macy prices [22]. The largest pack size was used when
estimating costs of commonly used maintenance drugs, the
appropriate pack size for the most common treatment
period among the subjects when estimating costs of drugs
(antibiotics and corticosteroids) due to exacerbations, and
the lowest prices when generic or parallel import options
were available.
The indirect costs included in the analysis were losses of
potential productivity incurred by sick-leave or early
retirement due to respiratory diseases, estimated accord-
ing to the human capital approach, as follows. Each sub-
ject’s average monthly salary [23] including payroll tax and
social security contributions [24e26] was used to calculate
the cost of each day’s absence from work due to sick-leave
and early retirement. Costs of early retirement were esti-
mated as the costs of absence from work every working day
before subjects were 65 years old (the most common
retirement age in Sweden), based on the percentage of the
disability pension (100%, 75%, etc.). Every month was
assumed to consist of 22 working days. This approach offers
a conceptual basis for valuing time costs and is the most
commonly used method today in Sweden [27,28].Statistical analysis
As results of cost-of-illness studies are typically skewed
(since costs for most subjects are low or zero), non-
parametric tests were used to test differences in costs
between groups, as follows. The KruskaleWallis Test was
used to evaluate the influence of COPD severity on costs
and resource use in 2010. The ManneWhitney U-test was
used (with Bonferroni correction where applicable) when
comparing costs in 1999 with costs in 2010 for specific COPD
severity stages. The Chi-square test was used to compare
demographics of the study sample and non-participants,
except for differences in age and percent predicted FEV1
for which independent T-tests were used. Differences be-
tween groups of subjects or study times were regarded as
significant if p < 0.05.
Mean annual costs and 95% confidence intervals (CI) for
eachCOPD stagewere acquired by bootstrappingwith 10,000
replicates [29]. The prevalence of COPD was estimated from
population-based analyses in 2008e2009 within the OLIN-
studies. The prevalence of each COPD severity stage was
Figure 1 Percentage distribution of direct costs by disease
severity in 1999 and 2010.
1934 S.-A. Jansson et al.then multiplied by the corresponding bootstrapped mean
cost to calculate the societal costs of COPD in Sweden.
Since costs of hospitalisations and outpatient care vary
among regions in Sweden, a simple sensitivity analysis
(scenario analysis) was performed based on two scenarios,
using the lowest unit costs for hospitalisations and outpa-
tient care in all regions in Sweden in one and the highest
unit costs in the other (for details of these costs see the
Online Appendix). We also performed a sensitivity analysis
for the total societal costs of COPD in Sweden using data on
COPD prevalence in Uppsala, Sweden, obtained in the
Burden of Obstructive Lung Disease (BOLD) studies [6].
Results
Resource use
Mean annual resource use per subject increased with
increasing severity of COPD (Table 3). Subjects with severe
and very severe COPD consumed significantly more
healthcare resources and drugs than subjects with mild and
moderate disease. A similar trend was found in productivity
losses due to early retirement.
Direct costs
The average annual direct costs of COPD also increased
significantly with disease severity, from 269 euros (SEK 2569)
for mild disease, through 1029 euros (SEK 9818) and 2201
euros (SEK 20,996) for moderate and severe disease,
respectively, to 5351 euros (SEK 51,052) for very severe
COPD. Hospitalisations were the main cost driver for very
severe subjects, and drugs for severe, mild and moderate
COPD. Itemised distributions of direct costs for each disease
severity stage are shown in Fig. 1. All of the direct cost items
were significantly correlated with disease severity (Table 4).
Indirect costs
The early retirement costs were considerably higher than
sick-leave costs for all severity stages, except mild COPD,Table 3 Average annual resource use and productivity losses p
COPD severity stage (
Very severe S
<30% 3
n Z 14 n
Direct cost items
Hospitalisations (number of days) 4.00 1
Drugs (number of drugs) 4.86 4
Outpatient care (number of visits) 2.93 3
Oxygen therapy (% of patients) 21.4 0
Indirect cost items
Early retirement (% of patients) 15.2 6
Sick-leave (number of days) 22.6 0
#p-value for KruskaleWallis test for differences in resource use betw
a Only 6 subjects were younger than 65 years, and of these, 4 subjewhere the main cost driver was sick-leave. The costs of
early retirement increased significantly with increasing
severity, but no statistically significant differences be-
tween severity stages were detected for the costs due to
sick-leave (Table 4).
Total costs
Mean annual total costs and itemised costs for each disease
severity stage are shown in Table 4. Indirect costs were
higher than direct costs for all severity stages.
A significant relationship was found between disease
severity and costs. The mean annual total cost per subject
with mild, moderate, severe and very severe COPD were
596 euros (SEK 5686) 3245 euros (SEK 30,957), 5686 euros
(SEK 54,242) and 17,355 euros (SEK 165,569), respectively.
These costs had a skewed distribution, with accordingly
wide confidence intervals.
Comparison of results between 1999 and 2010
Compared with costs recorded in the 1999 study, we found
lower total costs for subjects with severe and very severe
disease, but higher total costs for subjects with mild and




Z 29 n Z 85 n Z 116
.66 0.72 0.02 <0.001
.59 2.01 1.17 <0.001
.59 1.65 0.63 <0.001
.00 0.00 0.00 <0.001
.90 4.12 0.22 <0.001
.00a 0.71 1.14 0.305
een severity stages in 2010.
cts were early retired full-time or partly.
Table 4 The average annual societal costs per subject with COPD in 2010 by disease severity, euros.
COPD severity stage (GOLD) p-value#
Very severe Severe Moderate Mild
<30% 30e49% 50e79% 80%
n Z 14 n Z 29 n Z 85 n Z 116
Direct costs
Drugs 1407 961 478 181 <0.001
Hospitalisation 3299 830 425 11 <0.001
Outpatient care 469 410 126 77 <0.001
Oxygen therapy 176 0 0 0 <0.001
Total direct costs 5351 2201 1029 269 <0.001
Bootstrapped mean 5357 2194 1027 270
95% CI for Bootstrapped mean (2147e9610) (1379e3142) (621e1514) (177e328)
Indirect costs
Early retirement 7670 3485 2081 109 <0.001
Sick-leave 4334 0 135 218 0.305
Total indirect costs 12,004 3485 2216 327 0.091
Bootstrapped mean 12,007 3468 2212 328
95% CI for Bootstrapped mean (1832e23,980) (0e8277) (610e4321) (58e751)
TOTAL COSTS 17,355 5686 3245 596 <0.001
Bootstrapped mean 17,364 5662 3239 598
95% CI for bootstrapped mean (5838e31,196) (2068e10,815) (1403e5557) (274e1076)
#p-value for KruskaleWallis test for differences in costs between severity stages in 2010.
Costs of COPD 1935statistically significant (Fig. 2). Similarly, we found lower
costs for hospitalisations of subjects with severe and very
severe disease (Tables 4 and 5), but the only significant
changes were an increase in mean costs for outpatient care
of subjects with mild COPD and drugs of subjects with
moderate COPD.
Costs to society
The estimated annual total societal costs of COPD in Swe-
den in 2010 amounted to 1.46 bn euros (95% CI 0.62e2.55),
corresponding to SEK 13.9 billion. Direct and indirect costs
accounted for about 35% and 65% of the total costs,
respectively, and the costs were highly skewed: subjectsFigure 2 Average annual cost per subject with COPD by
disease severity in 1999 and 2010 (costs for 1999 adjusted to
2010 prices using the Consumer Price Index, in euros).with mild, moderate and severe/very severe COPD
accounted for 60%, 37% and 3% of the study population, but
20%, 66% and 14% of the total costs, respectively.
Sensitivity analysis
For the main analysis reported here the Northern Sweden
healthcare region’s price list of 2010 was used. In one of the
two sensitivity analyses, use of the lowest and highest
regional unit costs in Sweden for outpatient care and hos-
pitalisations decreased total societal costs by ca. 3% and
increased them by ca. 4%, respectively (see the Online
Appendix for details). In the other sensitivity analysis,
based on the prevalence of COPD in Uppsala (see above),
we found that total societal costs in Sweden amounted to
an estimated 1.25 bn euros (95% CI 0.50e2.26), corre-
sponding to SEK 11.9 billion. Direct and indirect cost
accounted for ca. 36% and 64% of the total costs,
respectively.
Discussion
The societal costs of COPD in Sweden are high; annual
estimated total costs amounted to 1.5 billion euros (SEK
13.9 bn) in 2010. Further, the costs were highly dependent
on disease severity, mean total costs for a subject with very
severe COPD being 29 times higher than for a subject with
mild COPD. The main disease-related cost drivers in direct
costs were hospitalisations in very severe subjects, but
drugs for severe, mild and moderate subjects. The main
cost driver in indirect costs was productivity loss due to
early retirement for all severity stages, except mild COPD,
where it was sick-leave.
Table 5 The average annual societal costs per subject with COPD in 1999 by disease severity indexed by Consumer Price Index
to 2010, euros.
COPD severity stage (GOLD)
Very severe Severe Moderate Mild
<30% 30e49% 50e79% 80%
n Z 8 n Z 48 n Z 123 n Z 33
Direct costs
Drugs 2173 1071 350a 98
Hospitalisation 9539 1289 163 0
Outpatient care 323 291 95 125a
Oxygen therapy 566 73 13 0
Total direct costsb 12,712 2744 654 223
Bootstrapped mean 12,696 2744 654 223
95% CI for Bootstrapped mean (3920e25,110) (1600e4203) (459e874) (105e367)
Indirect costs
Early retirement 9981 5763 1165 0
Absence from work 0 227 98 88
Total indirect costs 9981 5990 1263 88
Bootstrapped mean 10,062 5985 1260 88
95% CI for Bootstrapped mean (2303e19,963) (2813e9637) (471e2262) (0e263)
TOTAL COSTS 22,694 8734 1917 311
Bootstrapped mean 22,716 8733 1911 310
95% CI for Bootstrapped mean (6157e45,315) (5255e12,507) (1054e2931) (114e574)
a When performing tests of differences (ManneWhitney) between corresponding costs in 1999 (Table 5) and 2010 (Table 4), no sta-
tistically significant differences were found, except for outpatient care among subjects with mild COPD (pZ 0.032) and for drugs among
subjects with moderate COPD (p Z 0.022).
b Equipment aids are included in the total direct costs in 1999, however not separately specified here since they were not included in
2010.
1936 S.-A. Jansson et al.Compared to corresponding estimates obtained in 1999,
costs of hospitalisations had decreased, while costs of drugs
had increased. There are several possible explanations for
this shift in the distribution of direct costs. During the ten-
year period changes in the structure of the health-care
sector have resulted in fewer hospital beds. The number of
days in hospital due to COPD per 100,000 subjects per year
reportedly decreased by about 400 days in Sweden, and the
mean length of a hospitalisation due to COPD from 7.4 days
to 6.1 days over the decade [30]. We found similar trends,
with a decrease in the proportion of hospitalisations,
particularly for subjects with very severe COPD. However,
our study lacks sufficient statistical power for more
detailed analyses of the change in resource use by disease
severity. In addition, the introduction of some new drugs
and improvements in the implementation of treatment
guidelines [16] may have contributed to reductions in both
exacerbations and the number of hospitalisation days.
Another factor that may have contributed to the shift in the
distribution of direct costs is that subjects with COPD are
detected earlier today, so more subjects with mild and
moderate disease are under treatment today compared to
ten years ago. However, previous studies have shown that
COPD still is substantially under-diagnosed [5,6].
Data available from other countries confirm that hospi-
talisations is the most important cost driver among direct
costs [12,31]. Notably, it accounted for 54% of the direct
costs in the UK (2003), according to a bottom-up study [31],
and 43% of directs costs (drugs accounting for a further 40%)
for 1510 subjects with COPD attending general practitioners’practices in Spain monitored over a year (2003) [12]. A sig-
nificant relationship was found between costs and disease
severity in both these cited studies. Similarly, the US “Con-
fronting COPD” survey based on the general population
found that total costs were eight times higher on average for
subjects with severe COPD than for subjects with mild dis-
ease [32].
It should be noted that health economic data on COPD
are of varying quality and the estimates are often uncertain
for several reasons. Firstly, estimates quickly become
outdated, as unit costs, treatment patterns and the prev-
alence of diseases may change. Secondly, comparing data
obtained from multiple studies of costs associated with
diseases in different countries is not straightforward
because study design, unit costs, the structure of health-
care systems, the time periods covered and cost items
included may all differ [33]. Thirdly, most previous studies
have been top-down register studies, and several intending
to characterise costs of COPD among the general population
have been based on population samples with selection bias
of varying degrees, for instance based on data from general
practitioners or health maintenance organisations [10,12].
As COPD is substantially under-diagnosed [2,5,6,34], the
best currently available method for obtaining estimates of
its true costs in a given population is to prospectively
collect data on the consumption of health-care resources
and productivity losses for a cohort of well-defined subjects
who are fully representative of the population according to
age, gender and disease severity. The sample addressed in
the present study corresponds well with the general
Costs of COPD 1937population of northern Sweden. The estimations of costs
rely on self-reported health-care utilisation, but the pre-
cision of categorical data related to health-care utilisation
by subjects with COPD is considered to be high [35]. In
addition, we estimated annual societal costs using data
obtained from interviews with three-month intervals,
which is widely considered to be an adequate recall period
[18]. Furthermore, all interviews were performed by the
same person, and diaries were used after the first, second,
and third interviews to reduce the risk of recall bias.
Finally, the use of drugs was validated by subjects having
the drugs or their prescriptions at hand during the tele-
phone interviews.
The societal costs of COPD estimated from interviews of
subjects derived from the general population are generally
considerably higher than corresponding estimates obtained
from registry-based studies (mainly because of the sub-
stantial well-known under-diagnosis of COPD that still
persists) [34,36]. However, population-based studies such
as the one reported here have both strengths and weak-
nesses. One of the strengths is that data collected by in-
terviews are more detailed than data from official
registries. Furthermore, the estimated costs in this study
are based on recently collected data, which reflect current
guidelines for treating COPD. A possible weakness of our
study is the potential risk of recall bias. Another is that the
study is based on relatively few subjects, which could lead
to high variability in the data. However, overall the data
collected in this study is considered to be valid as a sample
from a large-scale population study with high participation
rate [15] was used, and the sample can be regarded as
representative of subjects with COPD in northern Sweden
living in both urban and rural areas.
Knowledge of current costs and cost drivers of different
diseases is useful for planning effective health-policy in-
terventions. As the prevalence of COPD increases with age,
the burden of the disease will probably be a greater prob-
lem in the future as a result of an ageing population in
several countries. If subjects with COPD would be identified
and diagnosed earlier in the disease progress, smoking
cessation could be introduced; a cost-effective treatment
and the only one known to have a substantial effect on
disease progression [37]. Revenues from sales of tobacco in
Sweden amount to SEK 10.6 billion in 2010, which is less
than the costs of COPD. Furthermore, smoking is also an
important risk factor for other diseases, including heart
diseases and lung cancer.
In conclusion, the costs of COPD are still high in Sweden.
Extrapolating the results to Sweden as a whole, the total
estimated costs for COPD in Sweden amounted to ca. 1.5
billion euros (SEK 13.9 bn) in 2010, with indirect costs ac-
counting for about 65% of the total costs. The costs are
highly dependent on disease severity but the total costs for
subjects with severe and very severe disease have
decreased, while costs for subjects with mild and moderate
disease have increased compared to ten years ago.Conflicts of interest
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